Who
W. Anthony Vernon
Director
Company insider
Files Form 4 as: Director, NovoCure; Director, Nuvation Bio; Director, McCormick & Company; Director, Intersect ENT; Director, Axovant Sciences; Director, WHITEWAVE FOODS Co; Director, Medivation; Chief Executive Officer, Kraft Foods Group.
In numbers
- Trades disclosed
- 195
- Buys
- 4
- Sells
- 8
- Bought
- $1.7M
- Sold
- $20.5M
- Companies
- 10
- Companies where not an officer
- 8
- First trade
- 14 Jul 2006
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,610 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,999 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,999 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,610 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $46K2,945 at $15.77 | filing |
| 2 Jun 2026filed 3 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $46K2,945 at $15.77 | filing |
| 21 May 2026filed 26 May 2026 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —123,397 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —123,397 at $0.00 | filing |
| 28 Apr 2026filed 28 Apr 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code M | $245K21,500 at $11.39 | filing |
| 28 Apr 2026filed 28 Apr 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code M | —21,500 at $0.00 | filing |
| 28 Apr 2026filed 28 Apr 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code M | —21,500 at $0.00 | filing |
| 28 Apr 2026filed 28 Apr 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code M | $245K21,500 at $11.39 | filing |
| 15 Feb 2026filed 18 Feb 2026 | MKC McCormick & CompanyFood Products | SEC FORM 4 Code M | —2,222 | filing |
| 15 Feb 2026filed 18 Feb 2026 | MKC McCormick & Companyoption or derivative · Food Products | SEC FORM 4 Code M | —2,222 | filing |
| 15 Feb 2026filed 18 Feb 2026 | MKC McCormick & Companyoption or derivative · Food Products | SEC FORM 4 Code M | —2,222 | filing |
| 15 Feb 2026filed 18 Feb 2026 | MKC McCormick & CompanyFood Products | SEC FORM 4 Code M | —2,222 | filing |
| 4 Jun 2025filed 6 Jun 2025 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,697 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,215 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $17K999 at $17.35 | filing |
| 21 May 2025filed 23 May 2025 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —292,983 at $0.00 | filing |
News
Reviewing NeurAxis (NASDAQ:NRXS) & NovoCure (NASDAQ:NVCR)NVCR · tickerreport.com · 15 Oct 2026NovoCure (NASDAQ:NVCR) and Medline (NASDAQ:MDLN) Financial AnalysisNVCR · themarketsdaily.com · 8 Oct 2026NovoCure (NASDAQ:NVCR) versus Kewaunee Scientific (NASDAQ:KEQU) Head-To-Head ReviewNVCR · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name W. Anthony Vernon; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.